Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Cell Cycle from quiescence, growth and DNA replication to mitosis and Cytokinesis showing cell cycle checkpoints.
When cells receive mitogens, they enter the cell cycle to synthesize new copies of their DNA in a series of steps that culminate in cell division.
iStock, ttsz

Do Cells Exit the Cell Cycle in Absence of Mitogens?

Finding could point toward more effective treatments to potentially prevent cancer relapse

National Institutes of Health
Published:Jul 05, 2023
|2 min read
Register for free to listen to this article
Listen with Speechify
0:00
5:00

A new study suggests that cells preparing to divide can reverse this process and return to a resting state, challenging long-held beliefs about cell division. If interrupted early in their preparation to divide, cells were able to halt going into mitosis. The finding—published recently in Nature and led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health—could point toward more effective treatments to interrupt cancer cell metastasis.

When cells receive growth-promoting signals, called mitogens, they enter the cell cycle to synthesize new copies of their DNA in a series of steps that culminate in cell division. Scientists have long thought that the preparatory stage of this cycle includes a point after which cells cannot halt the process. Researchers believed that after this “point of no return,” growth signals are no longer needed to drive cells to divide.

In the new study, scientists at NCI’s Center for Cancer Research captured videos of thousands of cells undergoing mitosis and watched what happened to those cells when mitogens were withdrawn. About 15 percent of the cells exited the cell cycle and returned to a resting state.

What those cells had in common was that they hadn’t been as far along as others in the cell cycle when they stopped receiving the mitogens. In experiments with many different kinds of cells, researchers found that all types of cells were capable of exiting the cell cycle—if it was early enough.

Drugs that inhibit the cell cycle regulators, cyclin-dependent kinase 4 and 6 (CDK4 and CDK6)—such as the breast cancer drug, palbociclib (Ibrance)—likely interrupt cells’ progression through the cell cycle differently than previously thought, the researchers said.

They are now looking at whether they can take advantage of this new molecular mechanism to design a more durable therapy by combining CDK4 and CDK6 inhibitors with traditional chemotherapy drugs that induce DNA damage.

- This press release was originally published on the National Institutes of Health website